<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DESCRIPTION: <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the second leading cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>deaths</z:hpo> for men and women in the United States </plain></SENT>
<SENT sid="1" pm="."><plain>The American College of Physicians (<z:chebi fb="65" ids="13534">ACP</z:chebi>) developed this guidance statement for clinicians by assessing the current guidelines developed by other organizations on screening for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>When multiple guidelines are available on a topic or when existing guidelines conflict, <z:chebi fb="65" ids="13534">ACP</z:chebi> believes that it is more valuable to provide clinicians with a rigorous review of the available guidelines rather than develop a new guideline on the same topic </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The authors searched the National Guideline Clearinghouse to identify guidelines developed in the United States </plain></SENT>
<SENT sid="4" pm="."><plain>Four guidelines met the inclusion criteria: a joint guideline developed by the American <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Society, the U.S </plain></SENT>
<SENT sid="5" pm="."><plain>Multi-Society Task Force on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal Cancer</z:e>, and the American College of Radiology and individual guidelines developed by the Institute for Clinical Systems Improvement, the U.S </plain></SENT>
<SENT sid="6" pm="."><plain>Preventive Services Task Force, and the American College of Radiology </plain></SENT>
<SENT sid="7" pm="."><plain>GUIDANCE STATEMENT 1: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians perform individualized assessment of risk for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in <z:hpo ids='HP_0000001'>all</z:hpo> adults </plain></SENT>
<SENT sid="8" pm="."><plain>GUIDANCE STATEMENT 2: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians screen for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in average-risk adults starting at the age of 50 years and in high-risk adults starting at the age of 40 years or 10 years younger than the age at which the youngest affected relative was diagnosed with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>GUIDANCE STATEMENT 3: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a screening test in patients who are at average risk </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="65" ids="13534">ACP</z:chebi> recommends using optical colonoscopy as a screening test in patients who are at high risk </plain></SENT>
<SENT sid="11" pm="."><plain>Clinicians should select the test based on the benefits and harms of the screening test, availability of the screening test, and patient preferences </plain></SENT>
<SENT sid="12" pm="."><plain>GUIDANCE STATEMENT 4: <z:chebi fb="65" ids="13534">ACP</z:chebi> recommends that clinicians stop screening for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in adults over the age of 75 years or in adults with a life expectancy of less than 10 years </plain></SENT>
</text></document>